Navigation Links
CuraGen Reports First Quarter 2008 Financial Results

- CR011-vcMMAE in Phase II for melanoma, to begin Phase II for breast

cancer -

- Conference call to be hosted today at 9:00 a.m. EDT -

BRANFORD, Conn., April 22 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN) today reported its financial results for the first quarter of 2008. For the quarter ended March 31, 2008, CuraGen reported a net loss of $6.8 million, or $0.12 per share, compared to a net loss of $17.0 million, or $0.31 per share, for the same period in 2007.

During the first quarter, CuraGen incurred costs totaling $1.5 million for milestones related to the advancement of CR011-vcMMAE into Phase II clinical development. Of the decrease in cash and investments of $7.6 million during the first quarter of 2008, $2.6 million was related to non-recurring restructuring payments and payments associated with a previously discontinued program.

As of March 31, 2008, CuraGen had cash, restricted cash and investments of approximately $107.4 million. Following this morning's announced transaction with TopoTarget A/S, CuraGen currently projects a total of approximately $145 million in cash, restricted cash and investments at April 30, 2008.

CuraGen has also revised its 2008 financial guidance. CuraGen anticipates ending 2008 with approximately $135 million of cash and investments compared to previously provided guidance of $90 million. During the second half of 2008, CuraGen anticipates using approximately $6 to $8 million of cash and investments to fund operations.

"During the first quarter we continued to make progress strengthening our balance sheet and working to enhance shareholder value. We believe that our increased cash position and reduced anticipated cash burn for 2008 provides us with ample resources to advance CR011-vcMMAE through Phase II and the ability to act on promising business development initiatives that could diversify our pipeline," commented Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen. "With the recent advancement of CR011-vcMMAE into Phase II, we also look forward to the presentation of updated clinical trial results on this program in June at the 2008 ASCO Annual Meeting."

In addition, CuraGen today announced plans to begin Phase II development of CR011-vcMMAE in metastatic breast cancer. The first study for this indication will be an uncontrolled clinical trial of CR011-vcMMAE for the treatment of patients with locally advanced or metastatic breast cancer who have received previous chemotherapy. Enrollment is scheduled to begin in the third quarter.

"GPNMB, the antigen recognized by the CR011 antibody-drug conjugate, has emerged as an important target in breast cancer. The unmet need and market potential of breast cancer make this an excellent opportunity for value creation with CR011-vcMMAE where we can leverage the experience we already have with the drug in melanoma," said Dr. Shannon, "and we look forward to providing data from the breast program as they emerge."

Upcoming Presentation on CR011-vcMMAE

ASCO 2008 Annual Meeting, May 30 - June 3, Chicago, IL

- "A Phase I/II Study of CR011-vcMMAE, an Antibody Toxin Conjugate Drug,

in Patients with Unresectable Stage III /IV Melanoma." Poster

discussion. Sunday, June 1, 2008 from 2:00 p.m. - 6:00 p.m. Poster

Board #: 18. Location: W375e.

Conference Call Details and Dial-in Information

Date: Tuesday, April 22, 2008

Time: 9:00 a.m. EDT

Dial-in: 877-272-5391 (domestic)

706-758-4315 (international)

Passcode: 44717174

Webcast: Access to the live webcast is available at

A replay of the conference call will be available starting at 12:00 p.m. Eastern time on Tuesday, April 22, 2008 through Thursday, May 22, 2008 by dialing 800-642-1687 (domestic) or 706-645-9291 (international). The passcode for the replay is 44717174. An archive of the webcast will be available for 30 days at

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit

Forward-Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to CuraGen's expenses, losses, cash burn and future cash and investment positions, including with respect to the first quarter and for fiscal year 2008, the timing and expected results of our clinical programs, including our ability to advance CR011-vcMMAE through Phase II clinical trials, and our ability to diversify our pipeline through business development initiatives, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in CuraGen's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward- looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Glenn Schulman, PharmD

Director of Investor Relations

(888) 436-6642



(in thousands, except per share data)

Three Months Ended

March 31,

2008 2007


Collaboration revenue $22 $22

Operating expenses:

Research and development 5,371 11,502

General and administrative 1,715 4,014

Total operating expenses 7,086 15,516

Loss from operations (7,064) (15,494)

Interest income 1,070 1,153

Interest expense (797) (1,628)

Loss from continuing operations

before income tax benefit (6,791) (15,969)

Income tax benefit 18 60

Loss from continuing operations (6,773) (15,909)

Loss from discontinued operations, net of tax - (1,138)

Net loss ($6,773) ($17,047)

Basic and diluted loss per share from

continuing operations $(0.12) $(0.29)

Basic and diluted loss per share from

discontinued operations - (0.02)

Basic and diluted net loss per share $(0.12) $(0.31)

Weighted average number of shares

used in computing basic and diluted

net loss per share 56,520 55,413


March 31, December 31,

2008 2007


Cash and investments $92,749 $100,444

Restricted cash 14,671 14,533

Total cash and investments and

restricted cash $107,420 $114,977

Working capital $102,475 $107,844

Total assets $111,230 $119,282

4% Convertible subordinated notes due 2011 $69,890 $69,890

Total long-term liabilities $70,953 $70,975

Accumulated deficit $494,347 $487,574

Stockholders' equity $32,822 $38,465


SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
2. CuraGen Reports Third Quarter 2007 Financial Results
3. CuraGen to Present at the Bear Stearns 20th Annual Healthcare Conference
4. Albemarle Reports Record Quarterly Net Sales and Operating Results
5. Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008
6. Amylin Pharmaceuticals Reports First Quarter Financial Results
7. QMed, Inc. Reports First Quarter Results
8. TeamStaff, Inc. Reports Preliminary Second Quarter 2008 Results
9. Bioniche Reports the Passing of its Board Chair
10. Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36
11. Torchmark Corporation Reports First Quarter 2008 Results
Post Your Comments:
(Date:11/25/2015)... ... 25, 2015 , ... In an ongoing Clinical Study conducted by an independent ... UV Angel is evaluating the efficacy of its product and its disinfection protocol. This ... beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical center ...
(Date:11/25/2015)... ... November 25, 2015 , ... In honor of Pulmonary ... individuals and groups responsible for advancing care for pulmonary hypertension (PH) patients and ... the public, will receive special recognition throughout 2016 as part of PHA’s 25th ...
(Date:11/25/2015)... ... ... Many people know of the common symptoms of low thyroid hormone (also known ... people who find their cholesterol levels and weight are creeping up are more likely ... don’t have any of the other symptoms. , Thyroid hormone plays a major role ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bunion ... in an early celebration of the early holiday shopping season. Starting Wednesday November ... (normally $33.95 ea). Black Friday promotional pricing is in addition to any automatic ...
(Date:11/24/2015)... ... November 24, 2015 , ... New patients who wish to seek ... dental implants at her Mississauga, ON practice. Dr. Williams has been providing ... of dental implants. , Missing teeth can lead to a variety of complications ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... -- The hope of bearing a child ... cycles. After failure of over 15 IVF cycles, Mrs. ... hopes that she would be able to conceive ever. But finally optimism prevailed as she ... of over 15 IVF cycles. India ... one last attempt with Gaudium IVF Center in New ...
(Date:11/24/2015)...  Thanks to a donor with a personal connection ... Sister Diane Grassilli Center for Women,s Health now offers ... San Francisco . Fred Ruhland ... a gift of $617,320 that allowed the Center to ... and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) mammography for ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
Breaking Medicine Technology: